Compare Grab Holdings Ltd. (GRAB) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Grab Holdings Ltd. vs Sanofi SA — how do they compare? Grab Holdings Ltd. trades at $3.16 (market cap $12.72B), while Sanofi SA trades at $40.02 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 7.5× Grab Holdings Ltd.'s market cap, and Sanofi SA pays a 6.01% dividend while Grab Holdings Ltd. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Grab Holdings Ltd. for 94 Days and Sanofi SA for 94 Days on average.
| GRAB | SNY | |
|---|---|---|
Market Cap | $12.72B | $95.18B |
Volume | 65,352,859 | 2,995,646 |
Sector | Technology | Health |
52-Week High | $6.17 | $52.34 |
52-Week Low | $2.80 | $39.51 |
Typical Hold Time | 94 Days | 94 Days |
Enterprise Value | $8.46B | $114.48B |
Dividend Yield | — | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GRAB trades at $3.08, up 0.33% with bearish technical signals but strong fundamentals. The company achieved profitability in 2025 with $268M net income and has beaten earnings estimates for three consecutive quarters. Recent developments include a $1.49B acquisition of Atome Financial and $30M in insider buying by the CEO, signaling confidence in growth prospects despite recent stock pressure.
GRAB presents a compelling turnaround story with accelerating revenue growth and margin expansion. The risk-reward appears favorable given the 92% analyst buy rating, though investors should monitor integration risks from the Atome acquisition and competitive pressures in Southeast Asian markets that could impact future profitability.
SNY trades at $40.2, up 1.62% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $46.72B in 2025, and net income improved to $7.81B. Analyst consensus is mixed, with 44% buy ratings. Recent news highlights a major immunology alliance expansion with Regeneron, valued up to $8B, signaling growth initiatives beyond Dupixent.
The outlook for SNY is cautiously optimistic, driven by earnings momentum and strategic partnerships, but faces risks from patent expirations and volatile cash flows. Investment opportunity lies in pipeline diversification and cost management, while investors should monitor competitive pressures and R&D execution. The stock's current valuation metrics suggest reasonable pricing relative to peers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Grab Holdings Ltd.
Grab Holdings Limited operates as a holding company. The Company, through its subsidiaries, develops delivery management, mobility, financial services, and enterprise software solutions. Grab Holdings serves customers worldwide.
Read more on GRAB →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
